Abstract
Intensifying systemic therapy improves outcomes in metastatic prostate cancer. As apalutamide and enzalutamide join abiraterone and docetaxel as treatment options for patients, the choice of therapy for individual patients becomes more complex. We anticipate precision targeted and immune therapies will build on the advances of recently completed large-scale trials.
| Original language | English (US) |
|---|---|
| Journal | Nature Reviews Urology |
| DOIs |
|
| State | Published - Jan 1 2019 |
Fingerprint
ASJC Scopus subject areas
- Urology
Cite this
Combining options in metastatic prostate cancer. / Kopp, Ryan; Beer, Tomasz (Tom).
In: Nature Reviews Urology, 01.01.2019.Research output: Contribution to journal › Comment/debate
}
TY - JOUR
T1 - Combining options in metastatic prostate cancer
AU - Kopp, Ryan
AU - Beer, Tomasz (Tom)
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Intensifying systemic therapy improves outcomes in metastatic prostate cancer. As apalutamide and enzalutamide join abiraterone and docetaxel as treatment options for patients, the choice of therapy for individual patients becomes more complex. We anticipate precision targeted and immune therapies will build on the advances of recently completed large-scale trials.
AB - Intensifying systemic therapy improves outcomes in metastatic prostate cancer. As apalutamide and enzalutamide join abiraterone and docetaxel as treatment options for patients, the choice of therapy for individual patients becomes more complex. We anticipate precision targeted and immune therapies will build on the advances of recently completed large-scale trials.
UR - http://www.scopus.com/inward/record.url?scp=85069468976&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85069468976&partnerID=8YFLogxK
U2 - 10.1038/s41585-019-0217-z
DO - 10.1038/s41585-019-0217-z
M3 - Comment/debate
JO - Nature Reviews Urology
JF - Nature Reviews Urology
SN - 1759-4812
ER -